J. Biol. Chem., Vol. 263, Issue 33, 17225-17228, 11, 1988

A surface component on GH3 pituitary cells that recognizes transforming growth factor-beta, activin, and inhibin

S Cheifetz, N Ling, R Guillemin and J Massague
Department of Biochemistry, University of Massachusetts Medical School, Worcester 01655.

We have examined the ability of various forms of activin and inhibin, which are structurally related to transforming growth factor-beta (TGF- beta), to interact with various types of cell surface TGF-beta binding sites. Activin AB, inhibin A, and inhibin B were unable to compete with 125I-TGF-beta 1 for binding to the TGF-beta receptor types I, II, or III that coexist in human skin fibroblasts, rat liver epithelial cells, and mink lung epithelial cells. In contrast, activins and inhibins effectively competed for TGF-beta 1 binding to GH3 rat pituitary tumor cells. Binding of TGF-beta 1 to GH3 cells was mediated by about 2700 sites/cell with a Kd = 90 pM. Affinity labeling of these GH3 binding sites by cross-linking to 125I-TGF-beta 1 yielded 70-74-kDa labeled complexes distinct from previously identified TGF-beta binding components. Labeling of these 70-74-kDa components with 125I-TGF-beta 1 was inhibited by TGF-beta 1, TGF-beta 2, activin AB, and inhibin B at concentrations in the high picomolar to low nanomolar range, but it was not significantly affected by other polypeptide hormones and growth factors tested. The 70-74-kDa labeled GH3 components represent a novel type of cell surface TGF-beta binding protein that is unique in its ability to recognize various other members of the TGF-beta family of bioactive polypeptides.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. G. Farnworth, Y. Wang, R. Escalona, P. Leembruggen, G. T. Ooi, and J. K. Findlay Transforming Growth Factor-{beta} Blocks Inhibin Binding to Different Target Cell Types in a Context-Dependent Manner through Dual Mechanisms Involving Betaglycan Endocrinology, November 1, 2007; 148(11): 5355 - 5368. [Abstract] [Full Text] [PDF]

				C. Boxall, S. T. Holgate, and D. E. Davies The contribution of transforming growth factor-{beta} and epidermal growth factor signalling to airway remodelling in chronic asthma Eur. Respir. J., January 1, 2006; 27(1): 208 - 229. [Abstract] [Full Text] [PDF]

				S. Yonemura, T. Matsui, S. Tsukita, and S. Tsukita Rho-dependent and -independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo J. Cell Sci., June 15, 2002; 115(12): 2569 - 2580. [Abstract] [Full Text] [PDF]

				Q. Liu, J. H. Grubb, S. S. Huang, W. S. Sly, and J. S. Huang The Mannose 6-Phosphate/Insulin-like Growth Factor-II Receptor Is a Substrate of Type V Transforming Growth Factor-beta Receptor J. Biol. Chem., July 9, 1999; 274(28): 20002 - 20010. [Abstract] [Full Text] [PDF]

				D. Ray and S. Melmed Pituitary Cytokine and Growth Factor Expression and Action Endocr. Rev., April 1, 1997; 18(2): 206 - 228. [Abstract] [Full Text]

				A. Moustakas, T. Takumi, H. Y. Lin, and H. F. Lodish GH3 Pituitary Tumor Cells Contain Heteromeric Type I and Type II Receptor Complexes for Transforming Growth Factor beta and Activin-A J. Biol. Chem., January 13, 1995; 270(2): 765 - 769. [Abstract] [Full Text] [PDF]

				H. Yamashita, T. Okadome, P. Franzén, P. t. Dijke, C.-H. Heldin, and K. Miyazono A Rat Pituitary Tumor Cell Line (GH(3)) Expresses Type I and Type II Receptors and Other Cell Surface Binding Protein(s) for Transforming Growth Factor-beta J. Biol. Chem., January 13, 1995; 270(2): 770 - 774. [Abstract] [Full Text] [PDF]

				S. Fanayan, S. M. Firth, A. J. Butt, and R. C. Baxter Growth Inhibition by Insulin-like Growth Factor-binding Protein-3 in T47D Breast Cancer Cells Requires Transforming Growth Factor-beta (TGF-beta ) and the Type II TGF-beta Receptor J. Biol. Chem., December 8, 2000; 275(50): 39146 - 39151. [Abstract] [Full Text] [PDF]